Kiniksa Pharmaceuticals Ltd (KNSA)

$19.67

-0.1

(-0.51%)

Market is closed - opens 7 PM, 21 May 2024

Insights on Kiniksa Pharmaceuticals Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 83.39M → 79.85M (in $), with an average decrease of 4.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 25.23M → -17.70M (in $), with an average decrease of 170.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 54.7% return, outperforming this stock by 6.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 226.3% return, outperforming this stock by 189.0%

Performance

  • $19.63
    $19.98
    $19.67
    downward going graph

    0.2%

    Downside

    Day's Volatility :1.75%

    Upside

    1.55%

    downward going graph
  • $13.25
    $22.09
    $19.67
    downward going graph

    32.64%

    Downside

    52 Weeks Volatility :40.02%

    Upside

    10.96%

    downward going graph

Returns

PeriodKiniksa Pharmaceuticals LtdSector (Health Care)Index (Russel 2000)
3 Months
-0.75%
0.8%
0.0%
6 Months
24.81%
13.4%
0.0%
1 Year
45.8%
11.4%
0.0%
3 Years
37.29%
17.7%
-19.9%

Highlights

Market Capitalization
1.4B
Book Value
$6.1
Earnings Per Share (EPS)
0.13
PE Ratio
154.69
Wall Street Target Price
30.8
Profit Margin
2.87%
Operating Margin TTM
-20.71%
Return On Assets TTM
-3.97%
Return On Equity TTM
2.11%
Revenue TTM
301.8M
Revenue Per Share TTM
4.29
Quarterly Revenue Growth YOY
65.2%
Gross Profit TTM
173.2M
EBITDA
-28.3M
Diluted Eps TTM
0.13
Quarterly Earnings Growth YOY
5.5
EPS Estimate Current Year
-0.11
EPS Estimate Next Year
0.58
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Kiniksa Pharmaceuticals Ltd(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 56.58%

Current $19.67
Target $30.80

Technicals Summary

Sell

Neutral

Buy

Kiniksa Pharmaceuticals Ltd is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
15.65%
24.81%
45.8%
37.29%
27.63%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
154.69
154.69
NA
-0.11
0.02
-0.04
NA
6.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Buy
$1.4B
27.63%
154.69
2.87%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • BlackRock Inc

    4.48%
  • Vanguard Group Inc

    4.18%
  • Rubric Capital Management LP

    4.10%
  • Fairmount Funds Management LLC

    4.06%
  • Baker Bros Advisors LP

    3.96%
  • Goldman Sachs Group Inc

    2.56%

Company Information

kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.

Organization
Kiniksa Pharmaceuticals Ltd
Employees
297
CEO
Mr. Sanj K. Patel
Industry
Health Technology

FAQs